Carnitine is a metabolic cofactor which is essential for normal fatty acid metabolism. Patients
with chronic kidney disease on dialysis have been shown both to suffer from disordered fatty …

Among the various metabolic abnormalities documented in dialysis patients are
abnormalities related to the metabolism of fatty acids. Aberrant fatty‐acid metabolism has …

Carnitine is a naturally occurring amino acid derivative that is involved in the transport of
long-chain fatty acids to the mitochondrial matrix. There, these substrates undergo β …

ABSTRACT L‐carnitine plays an essential role in the β‐oxidation of fatty acids by catalyzing
their transport into the mitochondrial matrix. The kidney maintains plasma free L‐carnitine …

Levocarnitine is available in both an intravenous and oral formulation. In December 1999
the US Food and Drug Administration (FDA) granted approval for the use of the intravenous …

BACKGROUND: Levocarnitine deficiency in hemodialysis patients is common. Although the
effect of intravenous levocarnitine therapy was studied in small trials, the effect on global …

Among the homeostatic processes controlling the endogenous l-carnitine pool in humans,
the kidney has a vital role through extensive and adaptive tubular reabsorption. Kidney …

ABSTRACT Beginning January 1, 2003, the Centers for Medicare and Medicaid Services
(CMS) initiated a national coverage determination for the use of levo‐carnitine (L‐carnitine) …

To the Editor: Despite the fact that levocarnitine (L-carnitine) injection has been used in
dialysis for more than 10 years and was approved specifically by the US Food and Drug …

Careful review of all available clinical trials of L-carnitine leads to the conclusion that there is
insufficient evidence to support the routine use of L-carnitine for any indication in dialysis …